Alchemyca Biotech | $2,500,000 | (Nov 22, 2024)
Dote | $1,447,585 | (Nov 22, 2024)
Iontra Inc | $45,000,000 | (Nov 22, 2024)
Causaly
United Kingdom
- London, England
- 14/07/2023
- Series B
- $60,000,000
Our mission at Causaly is to redefine the boundaries of human discovery by harnessing transformative AI technologies. Founded in 2018, Causaly’s unique AI platform is a powerful catalyst for the modern Life Science research organization, reshaping how data is found, analyzed and applied in critical decision-making processes in drug discovery and development.
Supporting a broad range of complex knowledge workflows, our platform accelerates the journey from bench research and laboratory insights to the launch of life-changing therapies.
- Industry Business Intelligence Platforms
- Website https://www.causaly.com/
- LinkedIn https://www.linkedin.com/company/causaly/
Related People
Yiannis KiachopoulosCo Founder
United Kingdom -
London Area
In Causaly we amplify human cognitive abilities to expand the boundaries of discovery towards making the best decisions in Biomedicine.
To achieve this, we are teaching computers to read all knowledge ever published and develop an interface that allows humans to answer questions they can’t ask anywhere else.
Enveda | $130,000,000 | (Nov 22, 2024)
Shinami | $5,645,000 | (Nov 22, 2024)
DANNCE.ai | $2,600,000 | (Nov 22, 2024)
Trustero | $10,000,000 | (Nov 22, 2024)
Lighthouse (UK) | $370,000,000 | (Nov 22, 2024)
Faircraft | $15,800,000 | (Nov 22, 2024)
Clean Skin Club | $32,000,000 | (Nov 22, 2024)
KeySavvy | $4,250,000 | (Nov 22, 2024)
Prompt Security | $18,000,000 | (Nov 21, 2024)